<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7041086/table_1" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 1</label>
  <p>Clinical and spirometric characteristics at baseline. Description and comparison between the three groups</p>
 </caption>
 <thead>
  <tr>
   <th rowspan="2" colspan="1" id="0-0-B-a"/>
   <th colspan="1" rowspan="1" id="0-1-.">Total</th>
   <th colspan="1" rowspan="1" id="0-2-.">VIG</th>
   <th colspan="1" rowspan="1" id="0-3-.">BIG</th>
   <th colspan="1" rowspan="1" id="0-4-.">CG</th>
   <th rowspan="2" colspan="1" id="0-5-B-a">
    <i>p</i>-value 
   </th>
  </tr>
  <tr>
   <th colspan="1" rowspan="1" id="1-1-.">
    <i>N</i> = 99 
   </th>
   <th colspan="1" rowspan="1" id="1-2-.">N = 38</th>
   <th colspan="1" rowspan="1" id="1-3-.">N = 25</th>
   <th colspan="1" rowspan="1" id="1-4-.">N = 36</th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td colspan="6">Main characteristics</td>
  </tr>
  <tr>
   <td> Age in years, median (IQR)</td>
   <td>57.5 (48.6–62.0)</td>
   <td>57.7 (52.4–60.3)</td>
   <td>57.7 (46.2–62.0)</td>
   <td>56.3 (49.9–63.3)</td>
   <td>0.92</td>
  </tr>
  <tr>
   <td> Masculine gender, n (%)</td>
   <td>64 (65)</td>
   <td>27 (71)</td>
   <td>18 (72)</td>
   <td>19 (53)</td>
   <td>0.17</td>
  </tr>
  <tr>
   <td colspan="6">Comorbidities at enrollment</td>
  </tr>
  <tr>
   <td> Renal dysfunction, n (%)</td>
   <td>9 (9)</td>
   <td>8 (21)</td>
   <td>1 (4)</td>
   <td>0 (0)</td>
   <td>0.01</td>
  </tr>
  <tr>
   <td> Diabetes mellitus, n (%)</td>
   <td>63 (64)</td>
   <td>23 (61)</td>
   <td>20 (80)</td>
   <td>20 (56)</td>
   <td>0.13</td>
  </tr>
  <tr>
   <td> Arterial hypertension, n (%)</td>
   <td>53 (54)</td>
   <td>22 (58)</td>
   <td>14 (56)</td>
   <td>17 (47)</td>
   <td>0.63</td>
  </tr>
  <tr>
   <td colspan="6">Underlying respiratory diseases</td>
  </tr>
  <tr>
   <td> Bronchial dilatation (%)</td>
   <td>6 (6)</td>
   <td>2 (5)</td>
   <td>3 (12)</td>
   <td>1 (3)</td>
   <td>0.38</td>
  </tr>
  <tr>
   <td> Emphysema/COPD (%)</td>
   <td>30 (30)</td>
   <td>14 (37)</td>
   <td>8 (32)</td>
   <td>8 (22)</td>
   <td>0.38</td>
  </tr>
  <tr>
   <td> Alpha-1 antitrypsine deficiency (%)</td>
   <td>8 (8)</td>
   <td>2 (5)</td>
   <td>2 (8)</td>
   <td>4 (11)</td>
   <td>0.74</td>
  </tr>
  <tr>
   <td> Pulmonary fibrosis (%)</td>
   <td>42 (42)</td>
   <td>15 (40)</td>
   <td>10 (40)</td>
   <td>17 (47)</td>
   <td>0.77</td>
  </tr>
  <tr>
   <td> Other interstitial disease (%)</td>
   <td>13 (13)</td>
   <td>5 (13)</td>
   <td>2 (8)</td>
   <td>6 (17)</td>
   <td>0.65</td>
  </tr>
  <tr>
   <td colspan="6">Immunosuppresive therapy</td>
  </tr>
  <tr>
   <td> Tacrolimus (%)</td>
   <td>89 (90)</td>
   <td>35 (92)</td>
   <td>24 (96)</td>
   <td>30 (83)</td>
   <td>0.27</td>
  </tr>
  <tr>
   <td> Mycophenolate mofetil (%)</td>
   <td>83 (84)</td>
   <td>31 (82)</td>
   <td>24 (96)</td>
   <td>29 (81)</td>
   <td>0.41</td>
  </tr>
  <tr>
   <td colspan="6">Graft features</td>
  </tr>
  <tr>
   <td> Second graft (%)</td>
   <td>3 (3)</td>
   <td>2 (5)</td>
   <td>1 (4)</td>
   <td>0 (0)</td>
   <td>0.47</td>
  </tr>
  <tr>
   <td> Bilateral lung transplant (%)</td>
   <td>26 (26)</td>
   <td>9 (24)</td>
   <td>8 (32)</td>
   <td>9 (25)</td>
   <td>0.75</td>
  </tr>
  <tr>
   <td> Prior viral respiratory infection (%)</td>
   <td>6 (6)</td>
   <td>2 (5)</td>
   <td>3 (12)</td>
   <td>1 (3)</td>
   <td>0.38</td>
  </tr>
  <tr>
   <td> Treatment for AR 3 months prior to inclusion (%)</td>
   <td>12 (12)</td>
   <td>9 (23)</td>
   <td>3 (12)</td>
   <td>0 (0)</td>
   <td>&lt; 0.01</td>
  </tr>
  <tr>
   <td colspan="6">Spirometric characteristics</td>
  </tr>
  <tr>
   <td> Last FEV-1 (mL/s)</td>
   <td>1670 (1410–2100)</td>
   <td>1670 (1410–2210)</td>
   <td>1620 (1410–2100)</td>
   <td>1770 (1498–2062)</td>
   <td>0.49</td>
  </tr>
  <tr>
   <td> BOS prior to enrollment 
    <sup>a</sup> (all stage) (%) 
   </td>
   <td>13 (13)</td>
   <td>9 (24)</td>
   <td>3 (12)</td>
   <td>1 (3)</td>
   <td>0.02</td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <i>Abbreviations: AR</i> acute rejection; 
   <i>BIG</i> bacterial infections group; 
   <i>CG</i> control group; 
   <i>COPD</i> Chronic obstructive pulmonary disease; 
   <i>FEV-1</i> forced expiratory volume in 1 s; 
   <i>VIG</i> viral infections group 
  </p>
  <p>
   <sup>
    <i>a</i>
   </sup>
   <i>last FEV-1/best FEV-1</i>
  </p>
 </tfoot>
</table>
